Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.

@article{Sylvester2002IntravesicalBC,
  title={Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.},
  author={R. Sylvester and A. van der Meijden and D. Lamm},
  journal={The Journal of urology},
  year={2002},
  volume={168 5},
  pages={
          1964-70
        }
}
PURPOSE We determine if intravesical bacillus Calmette-Guerin (BCG) reduces the risk of progression after transurethral resection to stage T2 disease or higher in patients with superficial (stage Ta, T1 or carcinoma in situ) bladder cancer. MATERIALS AND METHODS A meta-analysis was performed of the published results of randomized clinical trials comparing transurethral resection plus intravesical BCG to either resection alone or resection plus another treatment other than BCG. RESULTS We… Expand
Maintenance therapy with intravesical bacillus Calmette-Guerin in patients with intermediate- or high-risk non-muscle-invasive bladder cancer.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial.
  • H. Herr, D. Schwalb, +4 authors H. Oettgen
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1995
A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer.
...
1
2
3
4
...